Monsanto Roundup Lawsuit

Tuesday, March 25, 2008

GSK South Africa - Rolling in it

Been a bad 12 months for GlaxoSmithKline - Avandiagate, Seroxatgate plus falling shares. Garnier will be leaving soon and Andrew Witty will become the new CEO. Surely Garnier cannot leave GSK in the mess that it is?

Step forward the women of South Africa.

On the 27th February this year a cervical cancer vaccine was given to go-ahead for use in South Africa.

Cervarix is manufactured by GlaxoSmithKline whose medical director Navin Singh said the registration was a great step forward, as more women developed and died of cervical cancer than any other type of cancer in South Africa.

Nothing like scarmongering before a drug is launched huh.

Singh added, “The decision to approve GSK’s cervical cancer vaccine represents a great step forward for all South African women. Physicians will now have access to this important vaccine to help protect women against this disease,”

Hats off to GlaxoSmithKline. Cancer is a bastard of a disease.

Let's roll forward now to the present day.

The South African public have just learned that the price for this treatment is a whopping R700 an injection.

The vaccine is administered in a series of three injections.

R700 is approx £43.50. ($86.85)

Multiply that by 3 and you have quite a bit of money - £130.50 ($260.55)

Some price to pay for a vaccine that can prevent a disease women may or may not get.

More here

Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal

By Bob Fiddaman

ISBN: 978-1-84991-120-7